Professor Malcolm Ranson 

2010

• Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C. (2010). Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat, 120(2), 461-467. eScholarID:80158 | DOI:10.1007/s10549-010-0747-9
• Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, Schellens JH, Shapiro GI. (2010). Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Ann Oncol, 21(4), 884-894. eScholarID:80153 | DOI:10.1093/annonc/mdp377
• Dean EJ, Ward T, Pinilla C, Houghten R, Welsh K, Makin G, Ranson M, Dive C. (2010). A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. B J Cancer, 102(1), 97-103. eScholarID:80156 | DOI:10.1038/sj.bjc.6605418
• Ranson M, Shaw H, Wolf J, Hamilton M, McCarthy S, Dean E, Reid A, Judson I. (2010). A Phase 1 Dose-Escalation and Bioavailability Study of Oral and Intravenous Formulations of Erlotinib (Tarceva®, OSI-774) in Patients with Advanced Solid Tumors of Epithelial Origin. Cancer Chemotherapy Pharmacology, 66, 53-58. eScholarID:80157 | DOI:10.1007/s00280-009-1133-3

2009

• Board RE, Ellison G, Orr MC, Kemsley KR, McWalter G, Blockley LY, Dearden SP, Morris C, Ranson M, Cantarini MV, Dive C, Hughes A. (2009). Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer, 101(10), 1724-1730. eScholarID:80154 | DOI:10.1038/sj.bjc.6605371
• Colaco RJ, Menasce LP, Ranson M, Sobrinho-Simo M, Teijeiro JC, Vinjamuri S, Yap BK. (2009). Cribriform-murular variant of papillary thyroid carcinoma with neuroendocrine differentiation and aggressive behaviour in a patient with familial adenenomatous polyposis coli: a case report. Thyroid Science, 4, 1-3. eScholarID:80152
• Dean, EJ, Jodrell, D, Connolly, K, Danson, S, Jolivet, J, Durkin, J, Morris, S, Jowle, D, Ward, T, Cummings, J, Dickinson, G, Aarons, L, Lacasse, E, Robson, L, Dive, C, Ranson, MR. (2009). Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol, 27( 10), eScholarID:1d32675 | DOI:10.1200/JCO.2008.19.5677
• Hou JM, Greystoke A, Lee Lancashire L, Cummings C, Ward T, Board R, Ethan A,Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C; Blackhall F. (2009). Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. Am J Path, 175, 808-816. eScholarID:80155 | DOI:10.2353/ajpath.2009.090078
• Kefford, R, Thomas, N, Corrie, P, Palmer, C, Abdi, E, Kotasek, D, Beith, J, Ranson, MR, Mortimer, P, Watson, A, Margison, G, Middleton, M. (2009). A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. Br J Cancer, 100( 8), eScholarID:1d32677 | DOI:10.1038/sj.bjc.6605016
• Natale, R, Bodkin, D, Govindan, R, Sleckman, B, Rizvi, N, Capó, A, Germonpré, P, Eberhardt, W, Stockman, P, Kennedy, S, Ranson, MR. (2009). Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol, 27( 15), eScholarID:1d32442 | DOI:10.1200/JCO.2008.18.6015
• Watson AJ, Middleton MR, McGown G, Thorncroft M, Ranson M, Hersey P, McArthur G, Davis ID, Thompson D, Beith J, Haydon A, Kefford R, Lorigan P, Mortimer P, Sabharwal A, Hayward O, Margison GP. (2009). O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Br J Cancer, 100(8), 1250-1256. eScholarID:80150 | DOI:10.1038/sj.bjc.6605015

2008

• Board R, Thelwell N, Ravetto P, Little S, Ranson MR, Dive C, Hughes A, Whitcombe D. (2008). Multiplexed assays for detection of mutations in PIK3CA. Clin Chem, 54( 4), eScholarID:1d32661 | DOI:10.1373/clinchem.2007.098376
• Board R, Williams V, Knight L, Shaw J, Greystoke A, Ranson MR, Dive C, Blackhall FH, Hughes A. (2008). Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann N Y Acad Sci, 1137, eScholarID:1d32670 | DOI:10.1196/annals.1448.020
• Cummings J, Ward T, Greystoke A, Ranson MR, Dive C. (2008). Biomarker method validation in anticancer drug development. Br J Pharmacol, 153( 4), eScholarID:1d32663 | DOI:10.1038/sj.bjp.0707441
• Greystoke, A, Cummings, J, Ward, T, Simpson, K, Renehan, A, Butt, F, Moore, D, Gietema, J, Blackhall, FH, Ranson, MR, Hughes, A, Dive, C. (2008). Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol, 19( 5), eScholarID:1d32665 | DOI:10.1093/annonc/mdn014
• Khan, O, Ranson, MR, Michael, M, Olver, I, Levitt, N, Mortimer, P, Watson, A, Margison, G, Midgley, R, Middleton, M. (2008). A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer, 98( 10), eScholarID:1d32443 | DOI:10.1038/sj.bjc.6604366
• Ward T, Cummings J, Dean EJ, Greystoke A, Hou J, Backen A, Ranson MR, Dive C. (2008). Biomarkers of apoptosis. Br J Cancer, 99( 6), eScholarID:1d32674
• Ward TH, Cummings J, Dean EJ, Greystoke A, Hou JM, Backen A, Ranson MR, Dive C. (2008). Biomarkers of apoptosis. Br J Cancer, eScholarID:1d32678 | DOI:10.1038/sj.bjc.6604519

2007

• Danson S, Dean EJ, Dive C, Ranson MR. (2007). IAPs as a target for anticancer therapy. Curr Cancer Drug Targets, 7( 8), eScholarID:1d32662
• Danson S, Ranson MR, Denneny O, Cummings J, Ward T. (2007). Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial. Cancer Chemother Pharmacol, 60( 6), eScholarID:1d32683 | DOI:10.1007/s00280-007-0432-9
• Dean EJ, Ranson MR, Blackhall FH, Dive C. (2007). X-linked inhibitor of apoptosis protein as a therapeutic target. Expert Opin Ther Targets, 11( 11), eScholarID:1d32666 | DOI:10.1517/14728222.11.11.1459
• O'Byrne K, Danson S, Dunlop D, Botwood N, Taguchi F, Carbone D, Ranson MR. (2007). Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol, 25( 22), eScholarID:1d32682 | DOI:10.1200/JCO.2006.09.2791
• Ranson, MR, Hersey, P, Thompson, D, Beith, J, McArthur, G, Haydon, A, Davis, I, Kefford, R, Mortimer, P, Harris, P, Baka, S, Seebaran, A, Sabharwal, A, Watson, A, Margison, GP, Middleton, M. (2007). Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol, 25( 18), 2540-5. eScholarID:1d31289

2006

• Blackhall FH, Ranson MR, Thatcher N. (2006). Where next for gefitinib in patients with lung cancer? Lancet Oncol, 7( 6), 499-507. eScholarID:1d31579
• Cummings J, Ranson MR, Lacasse E, Ganganagari J, St-Jean M, Jayson G-, Durkin J, Dive C. (2006). Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer, 95( 1), 42-8. eScholarID:1d30991
• Ranson MR. (2006). Panitumumab : a viewpoint by malcolm ranson. Drugs, 66( 15), 2015-6. eScholarID:1d30910
• Ranson, MR, Middleton, M, Bridgewater, J, Lee, S, Dawson, M, Jowle, D, Halbert, G, Waller, S, McGrath, H, Gumbrell, L, McElhinney, R, Donnelly, D, McMurry, T, Margison, GP. (2006). Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res, 12( 5), 1577-84. eScholarID:1d13008 | DOI:10.1158/1078-0432.CCR-05-2198
• Taylor K, Micha D, Ranson MR, Dive C. (2006). Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain. Expert Opin Investig Drugs, 15( 6), 669-90. eScholarID:1d30901
• White S, Lorigan P, Margison GP, Margison J, Martin F, Thatcher N, Anderson H, Ranson MR. (2006). Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer, 95( 7), 822-8. eScholarID:1d30551
• Williams H, Julyan P, Ranson MR, Zweit J, Gillies J, Hastings D. (2006). Does (124)Iodo-deoxyuridine measure cell proliferation in NSCLC? Initial investigations with PET imaging and radio-metabolite analysis. Eur J Nucl Med Mol Imaging, eScholarID:1d31007

2005

• Baka S, Ranson MR, Lorigan P, Danson S, Linton K, Hoogendam I, Mettinger K, Thatcher N. (2005). A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer. Eur J Cancer, 41( 11), eScholarID:1d28865
• Cummings J, Ward T, LaCasse E, Lefebvre C, St-Jean M, Durkin J, Ranson MR, Dive C. (2005). Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer, 92( 3), eScholarID:1d28911
• Danson S, Blackhall FH, Hulse P, Ranson MR. (2005). Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf, 28( 2), 103-13. eScholarID:1d28902
• Jayson, G-, Mulatero, C, Ranson, MR, Zweit, J, Jackson, A, Broughton, L, Wagstaff, J, Hakansson, L, Groenewegen, G, Lawrance, J, Tang, M, Wauk, L, Levitt, D, Marreaud, S, Lehmann, F, Herold, M, Zwierzina, H, NULL. (2005). Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer, 41( 4), 555-63. eScholarID:1d28906
• Ranson MR, Jayson G-. (2005). Targeted antitumour therapy--future perspectives. Br J Cancer, 92 Suppl 1, S28-31. eScholarID:1d29452
• Swaisland H, Ranson MR, Smith R, Leadbetter J, Laight A, McKillop D, Wild M. (2005). Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet, 44( 10), eScholarID:1d29451
• Swaisland H, Smith R, Laight A, Kerr D, Ranson MR, Wilder-Smith C, Duvauchelle T. (2005). Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet, 44( 11), eScholarID:1d29651
• Valle JW, Dangoor A, Beech J, Sherlock D, Lee S, Scarffe J, Swindell R, Ranson MR. (2005). Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. Br J Cancer, 92( 4), 628-30. eScholarID:1d28925
• Ward T, Danson S, McGown A, Ranson MR, Coe N, Jayson G-, Cummings J, Hargreaves R, Butler J. (2005). Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone. Clin Cancer Res, 11( 7), 2695-701. eScholarID:1d30983

2004

• Barvaux V, Lorigan P, Ranson MR, Gillum A, McElhinney R, McMurry T, Margison GP. (2004). Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. Mol Cancer Ther, 3( 10), 1215-20. eScholarID:1d9364
• Barvaux V, Ranson MR, Brown R, McElhinney R, McMurry T, Margison GP. (2004). Dual repair modulation reverses Temozolomide resistance in vitro. Mol Cancer Ther, 3( 2), 123-7. eScholarID:1d9365
• Cummings J, Ward T, Ranson MR, Dive C. (2004). Apoptosis pathway-targeted drugs-from the bench to the clinic. Biochim Biophys Acta, 1705( 1), 53-66. eScholarID:1d29254
• Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G, Ranson MR. (2004). Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer, 90( 11), 2085-91. eScholarID:1d28999
• Danson S, Ward T, Butler J, Ranson MR. (2004). DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev, 30( 5), 437-49. eScholarID:1d30622
• Ranson MR, Wardell S. (2004). Gefitinib, a novel, orally administered agent for the treatment of cancer. J Clin Pharm Ther, 29( 2), 95-103. eScholarID:1d28714
• Ranson MR. (2004). Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer, 90( 12), 2250-5. eScholarID:1d28707

2003

• Danson, S, Lorigan, P, A. Arance, Clamp, A, Ranson, MR, J. Hodgetts, L. Lomax, L. Ashcroft, Thatcher, N, M.R. Middleton. (2003). Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma. Journal of Clinical Oncology, July, eScholarID:1d25113
• Danson, S, Lorigan, P, Arance, A, Clamp, A, Ranson, MR, Hodgetts, J, Lomax, L, Ashcroft, L, Thatcher, N, Middleton, M. (2003). Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol, 21( 13), 2551-7. eScholarID:1d9273 | DOI:10.1200/JCO.2003.10.039

2002

• Baselga, J, Rischin, D, Ranson, MR, Calvert, H, Raymond, E, Kieback, D, Kaye, S, Gianni, L, Harris, A, Bjork, T, Averbuch, S, Feyereislova, A, Swaisland, H, Rojo, F, Albanell, J. (2002). Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol, 20( 21), 4292-302. eScholarID:1d9367 | DOI:10.1200/JCO.2002.03.100
• Ranson MR, Mansoor A, Jayson G-. (2002). ZD1839 (Iressa) a selective epidermal growth factor receptor tyrosine kinase inhibitor. Anti Cancer Drugs, 2, eScholarID:1d33883
• Ranson, MR, Hammond, L, Ferry, D, Kris, M, Tullo, A, Murray, P, Miller, V, Averbuch, S, Ochs, J, Morris, C, Feyereislova, A, Swaisland, H, Rowinsky, E. (2002). ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol, 20( 9), 2240-50. eScholarID:1d9368

2001

• Blackhall FH Hancock BW Soukop M McGown AT Robbins A Halbert G, Cancer Research Campaign Phase I/II Committee, Ranson MR, Radford JA, Jayson G-. (2001). A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br J Cancer, 84, eScholarID:1d2170
• von Pawel, J, Gatzemeier, U, Pujol, J, Moreau, L, Bildat, S, Ranson, MR, Richardson, G, Steppert, C, Rivière, A, Camlett, I, Lane, S, Ross, G. (2001). Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol, 19( 6), 1743-9. eScholarID:1d9369